Relief Therapeutics Holding AG (0QKQ.L)
| Previous close | 0.0330 |
| Open | 0.0328 |
| Bid | 0.0000 x N/A |
| Ask | 0.0000 x N/A |
| Day's range | 0.0325 - 0.0329 |
| 52-week range | 0.0325 - 0.0329 |
| Volume | |
| Avg. volume | N/A |
| Market cap | 207,934 |
| Beta (5Y monthly) | -17.14 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.0100 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- EQS Group
Relief Therapeutics Announces Promising Initial Stability Data on a New Formulation of RLF-100® (Aviptadil)
Relief Therapeutics Holding SA / Key word(s): Research Update03-Aug-2022 / 07:00 CET/CESTRelease of an ad hoc announcement pursuant to Art. 53 LRThe issuer is solely responsible for the content of this announcement.Relief Therapeutics Announces Promising Initial Stability Data on a New Formulation of RLF-100® (Aviptadil)This new formulation may have important clinical uses for a variety of rare lung diseases Geneva, Switzerland, August 3, 2022 – RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: R
- EQS Group
Acer Therapeutics and Relief Therapeutics Announce ACER-001 IND Submission for the Treatment of Maple Syrup Urine Disease
Relief Therapeutics Holding SA / Key word(s): Regulatory Admission28-Jul-2022 / 07:05 CET/CESTRelease of an ad hoc announcement pursuant to Art. 53 LRThe issuer is solely responsible for the content of this announcement.Acer Therapeutics and Relief Therapeutics Announce ACER-001 IND Submission for the Treatment of Maple Syrup Urine DiseasePhase 2a trial initiation planned for the first half of 2023 subject to IND clearance and available capitalNEWTON, MA and GENEVA, SWITZERLAND – July 28, 2022 –
- EQS Group
Acer Therapeutics and Relief Therapeutics Announce FDA Acceptance for Review of NDA Resubmission for ACER-001 for Treatment of UCDs
Relief Therapeutics Holding SA / Key word(s): Regulatory Admission28-Jul-2022 / 07:00 CET/CESTRelease of an ad hoc announcement pursuant to Art. 53 LRThe issuer is solely responsible for the content of this announcement. Acer Therapeutics amd Relief Therapeutics Announce FDA Acceptance for Review of NDA Resubmission for ACER-001 for Treatment of UCDs Prescription Drug User Fee Act (PDUFA) target action date set for January 15, 2023 NEWTON, MA and GENEVA, SWITZERLAND – July 28, 2022 – Acer Therap
